Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia

International Journal of Hematology

Volumn 98, Issue 6, 2013, Pages 719-722

  Kojima, Minoru ^a,b   Machida, Shinichiro ^a,b   Sato, Ai ^a   Miyamoto, Mitsuki ^a   Moriuchi, Makiko ^a,b   Ohbayashi, Yoshiaki ^b   Ando, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

Deferasirox; Iron chelation; Iron overload; Pure red cell aplasia

Indexed keywords

CYCLOSPORIN A; DEFERASIROX; FERRITIN; GANCICLOVIR; IRON; STEROID; THYMOCYTE ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW BIOPSY; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MONITORING; DYSPNEA; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GRANULOPOIESIS; HEMATOCRIT; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON OVERLOAD; KARYOTYPE; LEUKOCYTE COUNT; LEUKOPENIA; MEGAKARYOPOIESIS; MIDDLE AGED; PURE RED CELL ANEMIA; REMISSION; RETICULOCYTE COUNT; THORAX RADIOGRAPHY; THYMECTOMY; THYMOMA; TREATMENT RESPONSE; VIRUS PNEUMONIA;

BENZOATES; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; HUMANS; IRON CHELATING AGENTS; MIDDLE AGED; RED-CELL APLASIA, PURE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84891167070     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1455-0     Document Type: Article

References (28)

1. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97(12):3995-7.
2. Dungarwalla M, Marsh JC, Tooze JA, Lucas G, Ouwehand W, Pettengell R, Dearden CE, Gordon Smith EC, Elebute MO. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol. 2007;86(3):191-7.
3. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114(4):891-8.
4. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res. 2005;29(10):1213-5.
5. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. EPIC Study Investigators. Haematologica. 2010;95(4):557-66.
6. Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a phase I study in Japan. Int J Hematol. 2008;88(1):73-81.
7. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-4.
8. Capalbo S, Spinosa G, Franzese MG, Palumbo G. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol. 2009;121(1):19-20.
9. Oliva EN, Ronco F, Marino A, Alati C, Praticò G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568-70.
10. Okabe H, Suzuki T, Omori T, Mori M, Uehara E, Hatano K, Ueda M, Matsuyama T, Toshima M, Qzaki K, Nagai T, Muroi K, Ozawa K. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki. 2009;50(11):1626-9.
11. Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol. 2012;129(2):72-7.
12. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D’Auria F, Grieco V, Bianchino G, Lerose R, Bochicchio GB, Musto P. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res. 2011;35(5):566-70.
13. Taher AT, Musallam KM, Koussa S, Inati A. Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Ann Hematol. 2009;88(12):1263-4.
14. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111(4):1010-22.
15. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87(7):3000-6.
16. Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G, Cilloni D. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95(8):1308-16.
17. Vreugdenhil G, Smeets M, Feelders RA, Van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol. 1993;89:57-60.
18. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 2010;95(8):1433-4.
19. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-90.
20. Louache F, Testa U, Pelicci P, Thomopoulos P, Titeux M, Rochant H. Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem. 1984;259(18):11576-82.
21. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met. 1990;3(3-4):183-7.
22. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, Kurokawa M. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95(2):149-59.
23. Zeok JV, Todd EP, Dillon M, DeSimone P, Utley JR. The role of thymectomy in red cell aplasia. Ann Thorac Surg. 1979;28(3):257-60.
24. Masaoka A, Hashimoto T, Shibata K, Yamakawa Y, Nakamae K, Iizuka M. Thymomas associated with pure red cell aplasia. Histologic and follow-up studies. Cancer. 1989;64(9):1872-8.
25. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006;135(3):405-7.
26. Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. PRCA Collaborative Study Group. Haematologica. 2008;93(1):27-33.
27. Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymoma: evidence of T-cell clonal disorder. Am J Hematol. 1997;54(4):324-8.
28. Fujishima N, Hirokawa M, Fujishima M, Wada C, Toyoshima I, Watanabe S, Sawada K. Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica. 2006;91(12 Suppl):ECR47.